• Valbiotis welcomed France’s final, unanimous adoption on July 20, 2026 of legislation to accelerate cardiovascular and neurovascular prevention.
• The law elevates prevention in national health strategy, reinforcing awareness on major cardiometabolic risk factors such as hypertension, diabetes, high cholesterol.
• Screening is expanded within existing programs to support earlier detection, longer-term monitoring, broader roles for community health professionals.
• Pharmacists are authorized to measure blood pressure as part of preventive care; workplace initiatives are предусмотрены to raise risk-factor awareness.
• Valbiotis said the policy shift aligns with its focus on early prevention via clinically tested dietary supplement solutions and related training for healthcare professionals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valbiotis SA published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.